Double‐bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS‐CoV‐2
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17010
Abstract: ABSTRACT SARS‐CoV‐2, affecting predominantly elderlies, was recognized as a global pandemic in March 11th, 2020; clinical signs and laboratory alterations are similar to previous coronavirus epidemics with lymphocytopenia and neutrophilia observed in severe cases. read more here.
Keywords: double bright; cell adoptive; cd56bright cd16bright; bright cd56bright ... See more keywords
CD56bright/CD16bright NK-cell adoptive immunotherapy in patients with concurrent CNS disease and relapsed or refractory (R/R) AML.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3025
Abstract: 3025Background: Patients (pts) with R/R AML and concurrent CNS disease rarely respond to chemotherapy and have a dismal prognosis. Adoptive immunotherapy (AI) with haploidentical ex vivo-activated/... read more here.
Keywords: concurrent cns; adoptive immunotherapy; cns disease; cd56bright cd16bright ... See more keywords